An update in endoscopic management of gastric cancer.

PURPOSE OF REVIEW: Gastric cancer remains a prevalent disease with a 5-year mortality rate of less than 25%. This review focuses on the endoscopic detection, staging, and management of gastric adenocarcinoma. RECENT FINDINGS: Confocal laser endomicroscopy and narrow band imaging have a 77-99.4% sensitivity for early cancer detection, a significant improvement when compared with white light endoscopy. Proper staging can be accomplished through endoscopic ultrasound and multidetector row-computed tomography, with accuracy as high as 90.1%. Endoscopic management of early gastric cancer is minimally invasive and can be preferable to surgery. In properly selected patients, endoscopic submucosal dissection has been found to have 100% 5-year survival. SUMMARY: The recent advances in gastric cancer have greatly improved the care we can offer our patients in gastric oncology. The emerging technologies will hopefully continue to promote this trend.

Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.

BACKGROUND & AIMS: The prevalence of and the most appropriate way to diagnose the primary biliary cirrhosis (PBC)-chronic autoimmune hepatitis (AIH) overlap syndrome are uncertain. We investigated the prevalence of PBC and AIH and their level of overlap at a tertiary referral center, along with clinical, biochemical, and serologic characteristics. METHODS: We reviewed data from all patients with PBC (n = 609) and/or AIH (n = 15) examined at the Tufts Medical Center (Boston, MA) from January 1, 2000, to June 20, 2006. PBC was diagnosed based on 2 of the following 3 results: 6 months of positive results in tests for cholestatic liver enzymes, a positive result in a test for antimitochondrial antibodies, or a liver biopsy that indicated PBC. AIH was defined as an alanine aminotransferase level of 200 U/L or greater (≥ 5-fold above normal), a liver biopsy that indicated severe interface hepatitis, and levels of immunoglobulin G 2-fold or greater than that of normal. RESULTS: Only 6 patients with PBC (1%) met the Paris criteria for the overlap syndrome. If we included 9 patients with PBC who did not meet the Paris criteria, but had results from liver enzyme tests and liver biopsy analyses that indicated improvement after treatment with prednisone, the prevalence was 15 (2.8%). This is at the low end of previously reported prevalence values for overlap of PBC and AIH (2%-20%). CONCLUSIONS: The prevalence of the PBC-AIH overlap syndrome varies among medical centers. We propose that if the definition of PBC-AIH overlap syndrome be modified to include patients with unequivocal responses to prednisone despite not meeting the Paris criteria, this would improve treatment of patients.

Autoimmune hemolytic anemia in patients with liver transplants for primary biliary cirrhosis: Three case reports and a review of the literature.

BACKGROUND: Hemolytic anemia is rare after liver transplant and is usually associated with ABO mistmatch, post-transplant lymphoproliferative disorders, or medications. CASE REPORTS: We report three patients who had undergone successful liver transplants for primary biliary cirrhosis (PBC) and developed direct antibody test positive autoimmune hemolytic anemia (AIHA) several years into uncomplicated post-transplant management. For two of the patients, the hemolysis responded to steroids and rituximab. One patient required a surgical splenectomy. DISCUSSION: AIHA is an immune-mediated hemolysis that has been reported in patients with PBC. There are no reports of AIHA in patients following liver transplantation for this disease. AIHA should be considered in stable PBC patients who develop anemia years after liver transplant.